Dr. Cantley was recently elected as Chairman of the Board of Trustees of the Hope Funds for Cancer Research, a charity dedicated to advancing innovative research for the most difficult-to-treat cancers.
Cantley Lab members have found that the gene PIP4K2C and its associated protein PI5P4Kγ play a role in the regulation of the immune system, with potential implications for cancer immunotherapy treatments.
High levels of vitamin C kill certain kinds of colorectal cancers in cell cultures and mice, according to a new study from the Cantley Lab. The findings suggest that scientists could one day harness vitamin C to develop targeted treatments.
The Association of American Cancer Institutes (AACI) presented the AACI Distinguished Scientist Award to Lewis Cantley, Ph.D., on October 26, during the 2015 AACI/CCAF Annual Meeting, in Washington, DC.
Postdoc Costas Lyssiotis is one of six recipients of The Tri-Institutional Breakout Awards for Junior Investigators, which was established in part by Dr. Cantley after he won the 2013 Breakthrough Prize in Life Sciences.
The Ross Prize, which includes a $50,000 gift, was formally presented to Dr. Cantley at the New York Academy of Sciences in Manhattan, followed by an academic lecture by Dr. Cantley and other preeminent researchers
A multi-institutional research team, led by Dr. Lewis Cantley and investigators at Weill Cornell Medical College, has identified a family of enzymes they say is crucial for the growth of cancers that have genetic aberrations in p53.
Dr. Lewis Cantley, a leading cancer researcher, credited with discovering a family of enzymes fundamental to understanding cancer, has been named director of the newly established Cancer Center at Weill Cornell Medical College and NewYork-Presbyterian Hospital.